Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Has Average Target Price of $293.45

Posted by Brenda Bartman on Nov 12th, 2026

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $293.00.

A number of equities analysts have recently commented on JAZZ shares. Barclays raised their price objective on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Citigroup began coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, September 30th. They issued a “buy” rating and a $325.00 target price on the stock. Truist Financial raised their price target on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Morgan Stanley boosted their price target on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Finally, Wells Fargo & Company upped their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th.

Check Out Our Latest Stock Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $248.24 on Monday. Jazz Pharmaceuticals has a 12 month low of $136.27 and a 12 month high of $266.38. The company has a current ratio of 1.82, a quick ratio of 1.64 and a debt-to-equity ratio of 1.09. The business’s 50 day simple moving average is $229.35 and its 200 day simple moving average is $218.88. The company has a market cap of $15.93 billion, a price-to-earnings ratio of 21.76, a PEG ratio of 0.45 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $8.13 earnings per share. Sell-side analysts forecast that Jazz Pharmaceuticals will post 11.08 EPS for the current year.

Insider Activity

In related news, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the sale, the executive vice president directly owned 65,686 shares of the company’s stock, valued at $16,401,794.20. This trade represents a 53.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena Patil sold 1,200 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total transaction of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. The trade was a 2.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 171,342 shares of company stock worth $41,420,491. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $25,000. Pension & Wealth Management Advisors Inc. purchased a new stake in Jazz Pharmaceuticals in the third quarter worth approximately $32,000. Ameritas Advisory Services LLC bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $47,000. Westpac Banking Corp bought a new position in Jazz Pharmaceuticals during the first quarter valued at approximately $51,000. Finally, Elevation Wealth Partners LLC raised its stake in shares of Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 158 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.